Nilotinib is a second generation BCR-ABL tyrosine kinase inhibitor, used for the treatment of patients with chronic and accelerated phase Philadelphia chromosome-positive CML resistant or intolerant to treatment with imatinib. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.